Previous 10 | Next 10 |
Revenue Growth of +5.9% at Actual Exchange Rates (AER); +1.5% at Constant Exchange Rate (CER) Driven by Growth & Launch Products Core Operating Profit Change of -13.3% at CER Reflecting Generic Impact and Investment in R&D and Data, Digital & Technology Three N...
2024-05-08 14:10:44 ET More on Takeda Pharmaceutical Takeda Pharmaceutical: Eohilia's FDA Approval Brings Tailwinds Takeda Pharmaceutical Company: Attractive Stock But Needs To Grow Net Profits New house bill to extend COVID-era telehealth flexibilities Brist...
2024-05-07 15:55:56 ET More on Teladoc Health Teladoc: Even UnitedHealth Is Turning Its Back On Telehealth Teladoc: Huge Execution Problem Teladoc Health, Inc. (TDOC) Q1 2024 Earnings Call Transcript Teladoc off 3% on bottom line miss; 2024 outlook range incl...
2024-05-07 05:10:21 ET Summary Grifols, a major player in global plasma extraction and processing, has experienced a significant 43% decline in stock price in 2024 following a bearish report from Gotham. KPMG and the Spanish regulator have offered a more favorable perspective base...
2024-05-02 12:28:33 ET Summary EXEL continues to successfully implement Farallon's restructuring suggestions. A pivotal decision on cabo's current patent litigation is due by end of 1H'24. Multiple billions of potential revenue are at stake. I'm not holding shares through the ...
2024-05-01 09:00:00 ET Summary April 2024 jobs report expected to show an increase of 250,000 jobs, indicating continued tightness in the labor market. Healthcare sector likely to add jobs, while drug manufacturers may struggle. Construction, government, energy, and beverage i...
2024-04-26 14:32:03 ET More on Bristol, Sanofi, Takeda Bristol-Myers Squibb Stock: Gloomy Q1 Earnings Trigger Justified Sell-Off Bristol-Myers Squibb Company (BMY) Q1 2024 Earnings Call Transcript Sanofi 2024 Q1 - Results - Earnings Call Presentation Takeda s...
− If Approved in the European Union, Fruquintinib Will Be the First Novel Targeted Therapy for Metastatic Colorectal Cancer Regardless of Biomarker Status in Over a Decade − Positive Opinion Based on Results from a Phase 3 Clinical Trial Which Demonstrated Significan...
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion based on results from FRESCO-2 Phase III clinical trial — ...
2024-04-25 18:28:44 ET Summary Neurocrine Biosciences, Inc. achieved positive results achieved from phase 2 SAVITRI study using NBI-1065845 for the treatment of patients with Major Depressive Disorder. NBI-1065845 may offer some advantages over currently approved MDD therapies, su...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
Takeda Pharmaceutical Company Limited American Depositary Shares Website:
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
2024-07-04 20:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary Meeting of Shareholders, held in Osaka today. Takeda's Board of Directors has 11 members servi...